CanBas Co

CanBas Co Inventory/Revenue

The Inventory to Revenue Ratio of CanBas Co (4575.T) as of Oct 19, 2026 is 2.00 %. In the previous year, Inventory to Revenue Ratio was 1.12 % — a change of 78.93% (higher).

Inventory/Revenue

2.00 %

YoY

78.93%

Last updated:

Inventory to Revenue Ratio of CanBas Co is 2022 2.00 % . Inventory to Revenue Ratio of CanBas Co was 2021 1.12 % . It decreases by 78.93% higher compared to the previous year.

The CanBas Co Inventory/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory/Revenue
Date
Inventory/Revenue
Jan 1, 2015
1.68 JPY
Jan 1, 2016
1.27 JPY
Jan 1, 2017
0.94 JPY
Jan 1, 2018
0.58 JPY
Jan 1, 2019
1.04 JPY
Jan 1, 2020
0.92 JPY
Jan 1, 2021
1.12 JPY
Jan 1, 2022
2.00 JPY
The CanBas Co Inventory/Revenue history
YEARInventory/RevenueYoY
2.00 %+78.93%
1.12 %+22.02%
0.92 %-12.00%
1.04 %+77.96%
0.58 %-37.66%
0.94 %-26.41%
1.27 %-24.37%
1.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Inventory to Revenue Ratio of CanBas Co is 2.00 % in 2022.

Inventory to Revenue Ratio of CanBas Co changed from 1.12 % to 2.00 %, representing a 78.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory to Revenue Ratio CanBas Co since 2006 – with annual values, charts, and detailed analysis.

The Inventory/Revenue ratio shows what percentage of revenue is held as inventory. Rising ratios may indicate slowing demand or inventory management issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory to Revenue Ratio's CanBas Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CanBas Co

All Key Metrics — CanBas Co